美股市场个股详情

REGN 再生元制药公司

添加自选

883.200
-7.480-0.84%

收盘价 04/26 16:00 (美东)

881.210
-1.990-0.23%

盘后 16:36 (美东)

973.16亿总市值25.40市盈率TTM

再生元制药公司股票讨论区

登录发表评论

Chen trader moo

04/22 17:37

大胆预测2024：Novavax的疫苗战略将如何重新定义全球健康

$诺瓦瓦克斯医药(NVAX.US)$
Novavax 2024：引领市场的疫苗巨头准备再次震撼世界
随着2024年的脚步日益临近，生物科技界的翘楚Novavax正站在新的里程碑前。去年，这家生物科技巨头启动了一场前所未有的公司转型，准备在股市上掀起一场风暴。随着研发（R&D）和销售、总务及行政（SG&A）费用的大幅削减，Novavax不仅展示了其财务纪律的钢铁意志，而且彰显了其在全球疫苗市场的领导地位。
财务重塑，剑指未来
在2023年，Novavax宣布了震撼行业的消息：将其运营成本削减至不可思议的7.5亿美元以下。这一战略决定不仅将公司塑造成为一个更加精干高效的战斗机器，还预示着其在2024年的股票市场上的强劲表现。公司的高层领导，包括敢于想象的总裁兼首席执行官John C. Jacobs，正带领Novavax走向前所未有的高峰。
疫苗市场的终极破局者
作为全球疫苗市场的创新领军者，Novavax不满足于现状。公司的COVID-19与流感联合疫苗的第三阶段试验即将启动，预计将为全球提供前...

技术分析挑战：如何判断一只股票是超买还是超卖？

Chen trader moo

04/22 17:10

Novavax 2024：策略转型引领未来股价飙升

$诺瓦瓦克斯医药(NVAX.US)$
Novavax 2024年：期待股价的显著表现
随着全球经济逐渐从疫情中恢复，生物技术公司Novavax正在通过一系列战略转型措施，准备迎接2024年的市场挑战。2023年，该公司启动了一项重大转型计划，包括显著减少研发（R&D）和销售、总务及行政（SG&A）开支的目标。通过这些战略调整，Novavax不仅优化了其财务状况，而且加强了其在优先市场交付差异化COVID-19疫苗的能力，同时加速了COVID-19与流感联合疫苗的研发进程。
财务表现和结构优化
Novavax在2023年第三季度财报电话会议上宣布，公司计划在2024年将研发及销售、总务及行政开支控制在7.5亿美元以下。此举是为了加强公司的财务状况并聚焦于核心竞争力的提升。同时，公司还宣布将全球员工总数减少约12%，预计完成后，公司的员工总数将比2023年第一季度末减少约30%。这一决策反映了公司追求更精简、更灵活的运营模式的战略方向。
市场机遇与未来展望
John C. Jacobs, Novavax的总裁...

通胀顽固不下，六月降息机会渺茫？

Mars Mooo

04/21 16:13

My trading plan for April 2024 to July 2024.

Hello Mooers!

Recently, there have been signs that World War 3

is coming (*1, *2, *3). Given the current status in the Middle East, Eastern Europe, and the Asia-Pacific, investing has become a difficult task.

In light of this hypothetical situation

, I have chosen to invest from April 2024 to July 2024 using a three-pronged strategy.

Approach One: Buy the winners
Who are the winners?

During wars, companies that are in the defense, oil, ...

My trading plan for April 2024 to July 2024.

Moomoo x Nasdaq：TotalView Level 2助力你的投资

Chen trader moo

04/19 09:33

Novavax to Supply Updated COVID-19 Vaccine to Private Healthcare Providers in the United Kingdom

$诺瓦瓦克斯医药(NVAX.US)$$Moderna(MRNA.US)$
April 18, 2024
For Global Investor Audience Only
Novavax’s Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) is now available to pharmacies across the United Kingdom (U.K.) for private healthcare providers to offer an updated protein-based non-mRNA option as part of the 2024 vaccination season.
To...

life is a blessing

04/12 10:50

ESPR is the Probably the Most Undervalued Stock on the Market, Offers 2500% Upside. 2 FDA Approved Blockbuster Drugs. Billions in Sales Expected. Buyout Expected.

$Esperion Therapeutics(ESPR.US)$ Esperion (ESPR) stock price has dropped from a recent high of $3.40 a share to $2.31 on FALSE claims of dilution. The price drop offers an amazing buying opportunity.
Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...

Movers and Shakers

04/11 20:15

专栏Today's Morning Movers and Top Ratings: NKE, AMZN, KMX, V and More

Morning Movers
Gapping up
$耐克(NKE.US)$ stock increased by 1.4% after the sportswear company revealed its Olympic kits, aiming to leverage the appeal of top athletes to attract more consumers.
$Alpine Immune(ALPN.US)$ stock surged over 36% after Vertex Pharmaceuticals announced its plan to acquire the biotech company for about $4.9 billion in cash, which would give Vertex access to a treatment for an autoimmune kidney disease.
$Rent the Runway(RENT.US)$ stock ju...

Meltyy

04/02 10:41

FDA PDUFA Update…

🗓️ Last week’s PDUFAs:
$Akebia Therapeutics(AKBA.US)$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$默沙东(MRK.US)$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$阿斯利康(AZN.US)$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$再生元制药公司(REGN.US)$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$阿斯利康(AZN.US)$ : 🤔
⇒...